# Endocrinology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ann Richards (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML019-SYN
- Date: 2026-03-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marcus Delgado, MD
- Calendar frame: modern shifted

- Requested by: Rosalind Teague, MD

## Reason for consultation

Low bone mass on DXA with a FRAX risk above the treatment thresholds in a 63-year-old woman after a fall with a hand fracture. Please confirm how to classify her, whether to treat and with what, and how to monitor. **S**

## History

Ms. Richards is seen at the request of Dr. Teague four weeks after her intake visit. She fell from standing height last year and broke her hand, and one account describes a second fall with an ankle fracture. She watched her mother live with fractures of the arm and hip and a curved back, and she wants to avoid that. She went through menopause in her early fifties and took no hormone therapy. She has never taken glucocorticoids or other drugs that harm bone. She smoked heavily for many years and stopped more than fifteen years ago, and she has not had alcohol for more than fifteen years. She walks and lifts weights, and since intake she has raised her calcium intake to about 1200 mg a day from food and taken vitamin D3 2000 units daily. She has no bone pain, kidney stones, or bowel symptoms. She travels most weeks for work and would like a treatment she does not have to remember daily. **S**

## Examination

| System | Finding |
|---|---|
| General | Well and animated; height 164.0 cm, weight 66.2 kg |
| Spine | No tenderness or kyphosis; occiput touches the wall |
| Mouth | Good dentition; no exposed bone |
| Thyroid | Not enlarged; no nodules |
| Gait and balance | Gait steady; tandem stance 8 seconds |

BP 122/74 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 66.2 kg; BMI 24.6 kg/m². All vital signs are synthetic.

## Data reviewed

Intake DXA of the spine and hip, the lateral spine vertebral fracture assessment, the FRAX calculation and its inputs, the secondary-causes tests, 25-hydroxyvitamin D, fasting CTX, the three-day food record, and the intake fall-risk assessment. The 24-hour urine calcium has not yet been collected. 

## Assessment

1. **Low bone mass with high fracture risk** (M85.89). By T-score this is low bone mass, not osteoporosis: the lowest value is -2.3 at the lumbar spine, and none is -2.5 or lower. The phrase early osteoporosis has no defined meaning and should not be used. A hand fracture is not one of the fractures that establishes osteoporosis on its own (hip or vertebra, or in low bone mass a proximal humerus, pelvis, or distal forearm fracture), but it followed a fall from standing height, so it is correctly entered as a previous fracture in FRAX. With that and her mother's hip fracture, FRAX is 22 percent for a major osteoporotic fracture and 3.6 percent for hip fracture, above the thresholds of 20 and 3 percent. Treatment is indicated by the BHOF 2022 and Endocrine Society thresholds, and AACE 2020 would call this osteoporosis on clinical grounds. By AACE 2020 she is in the very-high-risk group because of a fall with injury and a fracture within about the past year; she does not meet the Endocrine Society very-high-risk criteria, which center on severe or multiple vertebral fractures. **S**
2. **Drug choice**. Zoledronic acid 5 mg once a year is a first-line choice in both the high-risk and very-high-risk groups of AACE 2020 and is an initial therapy in the Endocrine Society guideline, with proven reduction of hip, vertebral, and nonvertebral fractures. Once-yearly dosing suits her travel. Anabolic therapy was discussed; with no vertebral fracture and no T-score below -2.5 it is not needed first, and it remains the option if she fractures on treatment. An oral bisphosphonate is a reasonable alternative. A selective estrogen receptor modulator is not suitable, because it has not been shown to reduce hip fractures and her hip risk is above threshold. Before the first dose, 25-hydroxyvitamin D must be 30 ng/mL or more, calcium and eGFR must be normal (creatinine clearance 35 mL/min or more), and a routine dental examination should be done. **S**
3. **Secondary causes**. Normal calcium, PTH, phosphate, magnesium, alkaline phosphatase, kidney function, TSH, and blood count make hyperparathyroidism, osteomalacia, thyroid excess, and myeloma unlikely. Vitamin D of 24 ng/mL is insufficient and is being corrected. The 24-hour urine calcium is still needed to exclude hypercalciuria before treatment. Celiac serology and protein electrophoresis are not needed without bowel symptoms, anemia, or an unexplained abnormal result. **S**
4. **Falls** (Z91.81). Falls cause most of her fracture risk outside the spine. Her tandem stance of 8 seconds shows impaired balance; a supervised balance and strength program is the most effective fall-prevention step. **S**
5. **Alcohol use disorder in sustained remission** (F10.21). Heavy alcohol use and smoking harm bone; her long abstinence from both removes them as current risk factors, so neither is entered as current in FRAX. Remission also lowers her fall risk. No change to the drug plan; avoid sedating medicines. **S**

## Recommendations

1. Treat: zoledronic acid 5 mg intravenously once a year, starting once 25-hydroxyvitamin D is 30 ng/mL or more, calcium and eGFR are normal, and a routine dental examination is done; recheck these at about three months.
2. Collect the 24-hour urine calcium before the first dose.
3. Acetaminophen for the aches and fever that can follow the first dose.
4. Continue vitamin D3 2000 units daily and about 1200 mg of calcium a day, mostly from food.
5. Supervised balance and strength program now, then a home program; weight-bearing exercise most days.
6. Fasting morning CTX three months after the first dose to confirm response; calcium and creatinine before each yearly dose; 25-hydroxyvitamin D yearly.
7. Repeat DXA of the spine and hip two years after starting, on the same scanner.
8. After three yearly doses, recalculate FRAX and reassess: a drug holiday of up to three years is reasonable if she has had no new fracture or injurious fall and the femoral neck T-score is above -2.5; if she remains at very high risk, continue to six yearly doses.
9. Height and fall-risk screen yearly, with repeat vertebral imaging if height falls 2 cm or more.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Teague the same day; the patient agrees with the plan and asked for once-yearly treatment. **S**

## Follow-up

Primary care will continue monitoring on the CMID osteoporosis schedule. Endocrinology will see her again for a fracture on treatment, a fall in bone density on the follow-up DXA, an abnormal secondary-causes result, or the drug-holiday decision after the third dose. **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026), Aether Forge
- The clinician's guide to prevention and treatment of osteoporosis (2022), Bone Health and Osteoporosis Foundation (LeBoff MS et al., Osteoporos Int 2022;33(10):2049-2102)
- American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020), AACE/ACE (Camacho PM et al., Endocr Pract 2020;26(Suppl 1):1-46)
- Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019), Endocrine Society (Eastell R et al., J Clin Endocrinol Metab 2019;104(5):1595-1622)
- Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update (2020), Endocrine Society (Shoback D et al., J Clin Endocrinol Metab 2020;105(3):587-594)
- STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026), Centers for Disease Control and Prevention
